Neuphoria Therapeutics (NEUP) Corporate presentation summary

Addressing unmet needs in neuropsychiatric disorders

• Nearly one in four adults are affected by stress and anxiety disorders annually, with limited effective treatments and no new therapies in over 25 years.

• Significant unmet needs exist for safer, non-habit-forming, and fast-acting therapies for social anxiety disorder (SAD) and post-traumatic stress disorder (PTSD).

• Current standard treatments like SSRIs and benzodiazepines have efficacy and safety limitations, including side effects and addiction risk.

Pipeline and clinical development

• The pipeline includes BNC210 for stress and anxiety disorders, with additional programs in Alzheimer's disease and cognitive disorders.

• BNC210 is a novel a7 nicotinic receptor negative allosteric modulator, showing broad-spectrum anxiolytic effects without sedation, addiction, or cognitive impairment.

• Clinical programs are advancing in SAD and PTSD, with multiple Phase 2 and Phase 3 trials planned or ongoing.

BNC210 in social anxiety disorder (SAD)

• Phase 2 PREVAIL trial showed BNC210 reduced anxiety during public speaking, with efficacy comparable to benzodiazepines and a placebo-like safety profile.

• BNC210 demonstrated rapid onset (~1 hour), durable effect, and no sedation or addiction potential.

• Phase 3 AFFIRM studies are designed with FDA alignment, focusing on as-needed dosing and robust efficacy endpoints.